Sage Journals: Discover world-class research

Abstract

Objectives

Proximal to mid-term effects of contrast excimer laser atherectomy (ELA) + drug-coated balloon (DCB) versus PTA + drug-coated balloon (DCB) in the treatment of new lesions in the femoral popliteal segment of patients with lower extremity arteriosclerosis and occlusion.

Methods

The clinical data of 105 patients with CT-confirmed femoropopliteal segment lesions (Rutherford grades 3–6) were retrospectively analyzed. According to the computerized randomization method, 58 patients (44 males, mean 72.41 ± 10.58 years) were divided into group A ELA + DCB dilation and 47 patients (35 males, mean 73.83 ± 11.56 years) in group B PTA + DCB dilation. The clinical indexes mainly included the occurrence of Rutherford grade, freedom from target lesion revascularization rate (FTLR), ankle-brachial index (ABI), stage I survival rate, and postoperative complications before, 6 months, and 12 months after surgery and were compared between the two groups.

Results

The treatment success rate was 100% in all patients. The Rutherford grading at 12 months after operation was significantly improved in both groups, but statistical analysis showed that the improvement was more significant in group A (87.93% vs 72.34%, p = 0.043); ABI (0.77 ± 0.22^abc vs 0.65 ± 0.10^abc, p = 0.001); FTLR (93.10% vs 78.72%, p = 0.031), respectively. First-stage patency rate (91.38% vs 74.47%, p < 0.001),; complications, and adverse events were not statistically significant between the two groups (p > 0.05).

Conclusions

ELA + DCB significantly improved the 1-year freedom from target lesion revascularization rate and stage 1 patency rate with no significant increase in complications or adverse events.

Keywords

Excimer laser atherectomy drug-coated balloon arteriosclerosis obliterans of the lower extremities femoral popliteal lesions freedom from target lesion revascularization

Get full access to this article

View all access options for this article.

References

Liao

Song

, et al. Randomized controlled trial of orchid drug-coated balloon versus standard percutaneous transluminal angioplasty for treatment of femoropopliteal artery in-stent restenosis. Int Angiol 2019; 38(5): 365–371. DOI: 10.23736/S0392-9590.19.04243-3.

Chen

Guo

Jiang

, et al. IN.PACT SFA clinical study using the IN.PACT Admiral drug-coated balloon in a Chinese patient population. J Endovasc Ther 2019; 26(4): 471–478. DOI: 10.1177/1526602819852084.

Yang

, et al. Excimer laser atherectomy combined with drug coated balloon angiopathy for the treatment of femoropoplite artisoclerosis obliterans. Ann R Coll Surg Engl 2022; 104(9): 667–672. DOI: 10.1308/rcsann.2021.0335.

Shishehbor

Jaff

. Percutaneous therapies for peripheral artery disease. Circulation 2016; 134(24): 2008–2027. DOI: 10.1161/CIRCULATIONAHA.116.022546.

Bunting

Garcia

. Peripheral atherectomy: a critical review. J Intervent Cardiol 2007; 20(6): 417–424. DOI: 10.1111/j.1540-8183.2007.00280.x.

Ben Hammamia

Ben Mrad

Derbel

, et al. Angioplastie de l’axe fémoro-poplité: résultats à court et à moyen terme [femoropopliteal angioplasty: short- and mid-term results]. J Med Vasc 2017; 42(4): 204–212. DOI: 10.1016/j.jdmv.2017.04.001.

Schillinger

Sabeti

Loewe

, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354(18): 1879–1888. DOI: 10.1056/NEJMoa051303.

Stolker

Cohen

Kennedy

Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Investigators , et al.. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv 2012; 5(6): 772–782. DOI: 10.1161/CIRCINTERVENTIONS.111.967802.

Kayssi

Al-Jundi

Papia

, et al. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries. Cochrane Database Syst Rev 2019; 1(1): CD012510. DOI: 10.1002/14651858.CD012510.pub2.

10.

Gandini

Del Giudice

Merolla

, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther 2013; 20(6): 805–814. DOI: 10.1583/13-4308MR.1.

11.

Singh

Armstrong

Laird

. Femoropopliteal in-stent restenosis: current treatment strategies. J Cardiovasc Surg 2014; 55(3): 325–333.

12.

Krankenberg

Tübler

Ingwersen

, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized femoral artery in-stent restenosis (FAIR) trial. Circulation 2015; 132(23): 2230–2236. DOI: 10.1161/CIRCULATIONAHA.115.017364.

13.

Jinnouchi

Inoue

Soga

, et al. Pathology of neointimal calcification in very late restenosis after bare metal stent implantation for superficial femoral artery. Int Heart J 2017; 58(4): 641–644. DOI: 10.1536/ihj.16-379.

14.

Cassese

Byrne

Ott

, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv 2012; 5(4): 582–589. DOI: 10.1161/CIRCINTERVENTIONS.112.969972.

15.

Shibui

Tsuchiyama

Masuda

, et al. Excimer laser coronary atherectomy prior to paclitaxel-coated balloon angioplasty for de novo coronary artery lesions. Laser Med Sci 2021; 36(1): 111–117. DOI: 10.1007/s10103-020-03019-w.

16.

Dave

Patlola

Kollmeyer

CELLO Investigators , et al.. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther 2009; 16(6): 665–675. DOI: 10.1583/09-2781.1.

17.

Kokkinidis

Behan

Jawaid

, et al. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-year outcomes. Cathet Cardiovasc Interv 2020; 95(3): 439–446. DOI: 10.1002/ccd.28636.

18.

Schmidt

Zeller

Sievert

, et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther 2014; 21(1): 52–60. DOI: 10.1583/13-4538R.1.

19.

Schmidt

Piorkowski

Görner

, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv 2016; 9(7): 715–724. DOI: 10.1016/j.jcin.2015.12.267.

Treatment of femoropopliteal arterial lesions with excimer laser atherectomy and drug-coated balloon